<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00555347</url>
  </required_header>
  <id_info>
    <org_study_id>IRB 07011901</org_study_id>
    <nct_id>NCT00555347</nct_id>
  </id_info>
  <brief_title>Use of Armodafinil for Fatigue in Sarcoidosis</brief_title>
  <official_title>Use of Armodafinil (R-modafinil) for Fatigue in Sarcoidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cephalon</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the effect of Armodafinil (Nuvigil) on fatigue and sleep in sarcoidosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be divided into two halves. Patients will receive either drug or placebo in
      the first half. Patients receiving active drug will be started at one dose and it can be
      increased at the second visit. Those patients randomized to placebo will also have their dose
      adjusted by the investigating physician. The physicians will be blinded as to whether the
      patient is receiving drug or placebo. In the second half of the study, patients will receive
      the opposite treatment.

      Patients will have complete detailed questionnaires regarding their fatigue, sleepiness, and
      overall quality of life.

      They will have sleep studies done at the start and after each half of the study to determine
      the effect of therapy on sleepiness.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the effect of Armodafinil (Nuvigil) on fatigue and sleep in sarcoidosis.</measure>
    <time_frame>Prospective</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the effect of Armodafinil (Nuvigil) on pulmonary function in sarcoidosis.</measure>
    <time_frame>Prospective</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the safety and tolerability of Armodafinil (Nuvigil) in sarcoidosis.</measure>
    <time_frame>Prospective</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Sarcoidosis</condition>
  <condition>Fatigue</condition>
  <condition>Sleepiness</condition>
  <arm_group>
    <arm_group_label>Armnodafinil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Armodafinil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Armodafinil</intervention_name>
    <description>Dosage 150-250 mg</description>
    <arm_group_label>Armnodafinil</arm_group_label>
    <other_name>Nuvigil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of sarcoidosis using standard criteria 15.

          -  Disease for more than one year

          -  On stable, systemic therapy

          -  Complain of fatigue which has been present for more than six months.

          -  Over 18 years of age

          -  Provide written informed consent.

        Exclusion Criteria:

          -  Pregnancy

          -  Change in therapy for sarcoidosis in prior three months

          -  History of ventricular arrythmias
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert P Baughman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2007</study_first_submitted>
  <study_first_submitted_qc>November 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2007</study_first_posted>
  <last_update_submitted>May 26, 2015</last_update_submitted>
  <last_update_submitted_qc>May 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cincinnati</investigator_affiliation>
    <investigator_full_name>Robert P Baughman</investigator_full_name>
    <investigator_title>Prof Medicine</investigator_title>
  </responsible_party>
  <keyword>Sarcoidosis</keyword>
  <keyword>Fatigue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatigue</mesh_term>
    <mesh_term>Sarcoidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Armodafinil</mesh_term>
    <mesh_term>Modafinil</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>December 4, 2015</submitted>
    <returned>January 8, 2016</returned>
    <submitted>January 31, 2018</submitted>
    <returned>February 28, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

